You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 10,144,776


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,144,776
Title:Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer\'s disease are provided.
Inventor(s): Frey; William H. (White Bear Lake, MN), Hanson; Leah Ranae Bresin (Vadnais Heights, MN), Pokropinski; Sharon (Schaumburg, IL), Rausa; Francisco M. (Vernon Hills, IL)
Assignee: Baxalta Incorporated (Bannockburn, IL) Baxalta GmbH (Zug, CH)
Application Number:15/335,027
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Claims and Patent Landscape of U.S. Patent 10,144,776

Introduction

U.S. Patent 10,144,776, like any other patent, is a complex document that requires a thorough analysis to understand its claims, scope, and position within the broader patent landscape. This article will delve into the key aspects of this patent, including the criteria for patentability, the process of patent prosecution, and the importance of accurate inventorship.

Criteria for Patentability

To be granted, a patent must meet the criteria of novelty, usefulness, and non-obviousness as defined by U.S. patent law[3].

Novelty

The invention must be new and not previously known, sold, or used by others or by the inventors themselves. This includes ensuring that the invention was not publicly disclosed before the patent application was filed.

Usefulness

The invention must have a practical application and be capable of being used for its intended purpose. This means the invention must be functional and serve a useful purpose.

Non-obviousness

The invention must be significantly different from existing technology and not obvious to a person with ordinary skill in the relevant field. This is often the most challenging criterion to meet, as it requires demonstrating that the invention is a substantial improvement over prior art.

The Patent Prosecution Process

The journey from filing a patent application to receiving a granted patent is lengthy and complex.

Filing a Provisional Patent Application

The process often begins with the filing of a provisional patent application, which provides a temporary protection for one year. During this period, the applicant must decide whether to proceed with a non-provisional patent application[3].

Non-Provisional Patent Application

If the decision is made to proceed, a non-provisional patent application is filed, which starts the national phase of the patent process. This application is reviewed by a patent examiner to determine if the invention meets the criteria for patentability.

Examination and Prosecution

The patent examiner reviews the application, and if the claimed invention is not patentable as submitted, the examiner will issue rejections or objections. The applicant can then argue or amend the claims to address these issues. This process can take several years, with the average duration being between two to five years[3].

Continuation Procedures

During the prosecution process, applicants may use continuation procedures to further pursue their patent claims.

Types of Continuations

Continuations can be non-serialized or serialized. Non-serialized continuations, such as Requests for Continued Examination (RCEs), allow the applicant to continue the examination process without receiving a new serial number. Serialized continuations involve filing new applications that are related to the original application but receive a new serial number[1].

Importance of Accurate Inventorship

Determining the correct inventors is crucial for the validity and enforceability of a patent.

Conception and Reduction to Practice

Inventorship is determined based on who conceived the idea or subject matter of the patent claims. Conception is complete when the idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation[5].

Correct Identification of Inventors

Only those who conceived the subject matter of at least one claim of the patent are considered inventors. Incorrect or incomplete identification of inventors can lead to the patent being invalid and unenforceable, even if corrected later[5].

Patent Allowance Rates

Understanding the probability of receiving a patent is essential for applicants.

Measures of Patent Allowance Rates

There are several measures, including the first-action allowance rate, progenitor allowance rate, and family allowance rate. These rates provide insights into the likelihood of a patent being granted based on different criteria, such as the proportion of applications allowed without further examination or the proportion that produce at least one patent through continuation procedures[1].

Patent Litigation Complexity

Patent litigation is known for its complexity and high costs.

Metrics of Complexity

Studies have defined robust metrics to measure the complexity of patent litigation, including the duration of cases, defense and enforcement costs, and the impact of policy changes. These metrics help in understanding the factors associated with high complexity and how it affects patent rights[2].

Costs Associated with Patenting

The process of obtaining and maintaining a patent is costly.

Filing and Prosecution Costs

Drafting and filing a U.S. non-provisional patent application can cost between $8,000 and $20,000. Additional costs are incurred during the prosecution process, and the total cost over the lifetime of a patent can exceed $30,000[3].

International Patents

International patents can cost several times more than U.S. patents, making global patent protection a significant financial commitment.

Commercial Considerations

The decision to pursue patent protection is not solely based on legal criteria but also on commercial viability.

Market Potential

The commercial potential of the invention is a key factor in deciding whether to file a patent application. Even if an invention is patentable, other forms of intellectual property protection or strategies might be more effective[3].

Key Takeaways

  • Patentability Criteria: A patent must be novel, useful, and non-obvious to be granted.
  • Patent Prosecution: The process involves filing provisional and non-provisional applications, with potential continuation procedures.
  • Inventorship: Accurate identification of inventors is crucial for the validity and enforceability of a patent.
  • Patent Allowance Rates: Various measures indicate the likelihood of a patent being granted.
  • Patent Litigation: Litigation is complex and costly, affecting both large producers and small inventors.
  • Costs: The process of obtaining and maintaining a patent is financially significant.

FAQs

Q: What are the main criteria for a patent to be granted in the United States?

A: The main criteria are novelty, usefulness, and non-obviousness.

Q: How long does the patent prosecution process typically take?

A: The process can take between two to five years, with some applications pending longer.

Q: What is the importance of accurate inventorship in a patent application?

A: Accurate inventorship is crucial for the validity and enforceability of a patent, as incorrect identification can lead to the patent being invalid.

Q: What are continuation procedures in patent prosecution?

A: Continuation procedures allow applicants to further pursue their patent claims through non-serialized or serialized continuations.

Q: How costly is the process of obtaining and maintaining a patent?

A: The costs can range from $8,000 to $20,000 for filing and prosecution, with total lifetime costs often exceeding $30,000.

Sources

  1. What Is the Probability of Receiving a US Patent? - Yale Journal of Law & Technology[1]
  2. Opening Pandora's Box: Analyzing the Complexity of U.S. Patent Litigation - Yale Journal of Law & Technology[2]
  3. Intellectual Property Protection - KU Office of Research[3]
  4. Antibody-containing stabilizing preparation - PubChem[4]
  5. Determining Inventorship for US Patent Applications - Oregon State University[5]

More… ↓

⤷  Subscribe

Details for Patent 10,144,776

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Csl Behring Ag CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN immune globulin intravenous (human) For Injection 102367 July 27, 2000 10,144,776 2033-02-26
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 July 26, 2007 10,144,776 2033-02-26
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 October 02, 2009 10,144,776 2033-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.